Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 6/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 6/20 | 0.34 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.31 |
| ▸ | PDE4A | P27815 | 1/20 | 0.30 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.30 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.30 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10239723 | 0.91 | HCRTR1 (0.33) | HCRTR1HCRTR2SCN10A | |
| SCHEMBL10239944 | 0.87 | HCRTR2 (0.40) | HCRTR1HCRTR2 | |
| SCHEMBL10241598 | 0.86 | HCRTR1 (0.35) | HCRTR1HCRTR2 | |
| SCHEMBL2618758 | 0.85 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL10241632 | 0.82 | HCRTR2 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL2618596 | 0.82 | HCRTR1 (0.39) | HCRTR1HCRTR2 | |
| SCHEMBL10241205 | 0.82 | HCRTR2 (0.43) | HCRTR1HCRTR2 | |
| SCHEMBL9950292 | 0.79 | HCRTR2 (0.55) | HCRTR1HCRTR2 | |
| SCHEMBL10239720 | 0.77 | HCRTR1 (0.34) | HCRTR1HCRTR2 | |
| SCHEMBL10239683 | 0.77 | HCRTR2 (0.41) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165339-A1 | CYCLOPROPANE DERIVATIVES | HCRTR2, HCRTR1, CNR1 | HCRTR1 2/4885HCRTR2 1/4885SCN10A 1048/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.